The sales in the sector of the so-called Bioeconomy, has grown from 2.98% GDP (PIB in Spanish) in 2008 to 7.8% in 2012, according to the Asebio report, recently published. Companies stating that biotechnology is their main or only activity –among which Bionaturis is- registered an increase of 10.78% in their sales (8,800 million Euros) and 5% of rise in net employment during 2012, surpassing its own expectations for a year that it has been forecasted very complicated for Spanish economy.

According to Bionaturis’ CEO, Victor Infante, who attended the ASEBIO gala , “apart from the figures that prove that the biotech sector has performed better than others at this time of recession, I´d like to stand out some words heard today such as the need of innovation in all fields, including the relationship with public administrations, patients associations, regulatory authorities, partners at the value chain, with the main goal of seeking sustainability of the health system as a whole; or those promoting to seek talent wherever it is”.

More internationalization

85% of Asebio’s members conducted some international activity in 2013, as Bionaturis did. For the first time since this survey has been done, the associated companies consider LATAM as one of their priority market in their international strategy, specially Mexico (96.67%) and Colombia (95.83%). The European Union (93.24%), Switzerland (90.48%) and USA (88.41%) keep on having a leadership position for international operations.

During 2013, 57 companies and Spanish Organizations from the biotechnological sector (+39% regarding to 2012) signed a total of 108 international business partnerships (+42%).